Arcus Change In Cash vs Begin Period Cash Flow Analysis

RCUS Stock

USD 15.44 0.36 2.28%

Arcus Biosciences financial indicator trend analysis is way more than just evaluating Arcus Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcus Biosciences is a good investment. Please check the relationship between Arcus Biosciences Change In Cash and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

Change In Cash vs Begin Period Cash Flow

Change In Cash vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcus Biosciences Change In Cash account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Arcus Biosciences' Change In Cash and Begin Period Cash Flow is -0.54. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Arcus Biosciences, assuming nothing else is changed. The correlation between historical values of Arcus Biosciences' Change In Cash and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Arcus Biosciences are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Change In Cash i.e., Arcus Biosciences' Change In Cash and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.54

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Change In Cash

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Arcus Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 6.3 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (4.36).

	2021	2022	2023	2024 (projected)
Interest Income	657K	16M	41M	43.1M
Net Interest Income	397K	14M	39M	41.0M

Interest Income Net Interest Income

Arcus Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Preferred Stock Total Equity
Total Assets		0.91	0.97	0.99	0.92	0.93	0.85	-0.21	-0.73	0.85	0.88	0.86	0.79	0.76	0.92	0.67	0.95	0.86	0.98	0.9	0.72	0.53	0.99	0.95	0.89	0.68
Other Current Liab	0.91		0.94	0.86	0.97	0.94	0.65	-0.42	-0.92	0.9	0.86	0.66	0.56	0.74	0.92	0.38	0.9	0.9	0.91	0.96	0.89	0.22	0.92	0.84	0.73	0.6
Total Current Liabilities	0.97	0.94		0.93	0.91	0.93	0.72	-0.38	-0.82	0.95	0.91	0.72	0.62	0.85	0.97	0.48	0.96	0.95	0.96	0.93	0.76	0.41	0.98	0.88	0.78	0.71
Total Stockholder Equity	0.99	0.86	0.93		0.88	0.92	0.85	-0.23	-0.67	0.81	0.89	0.85	0.8	0.77	0.9	0.7	0.92	0.83	0.94	0.88	0.65	0.63	0.95	0.91	0.86	0.69
Other Liab	0.92	0.97	0.91	0.88		0.96	0.79	-0.28	-0.88	0.8	0.78	0.79	0.71	0.66	0.84	0.56	0.91	0.8	0.94	0.95	0.92	0.31	0.94	0.9	0.85	0.61
Net Tangible Assets	0.93	0.94	0.93	0.92	0.96		0.76	-0.37	-0.88	0.83	0.81	0.75	0.68	0.77	0.88	0.53	0.93	0.86	0.9	0.99	0.86	0.44	0.92	0.85	0.8	0.71
Property Plant And Equipment Net	0.85	0.65	0.72	0.85	0.79	0.76		0.14	-0.44	0.47	0.56	0.99	0.99	0.46	0.58	0.94	0.74	0.47	0.85	0.68	0.58	0.69	0.82	0.9	0.98	0.48
Net Debt	-0.21	-0.42	-0.38	-0.23	-0.28	-0.37	0.14		0.58	-0.58	-0.52	0.21	0.28	-0.71	-0.46	0.39	-0.37	-0.56	-0.13	-0.45	-0.34	-0.03	-0.2	0.05	0.13	-0.42
Retained Earnings	-0.73	-0.92	-0.82	-0.67	-0.88	-0.88	-0.44	0.58		-0.82	-0.69	-0.42	-0.32	-0.69	-0.79	-0.13	-0.84	-0.83	-0.73	-0.93	-0.94	-0.06	-0.76	-0.63	-0.55	-0.66
Accounts Payable	0.85	0.9	0.95	0.81	0.8	0.83	0.47	-0.58	-0.82		0.93	0.47	0.36	0.9	0.97	0.2	0.87	0.98	0.82	0.86	0.67	0.27	0.86	0.7	0.55	0.64
Cash	0.88	0.86	0.91	0.89	0.78	0.81	0.56	-0.52	-0.69	0.93		0.56	0.48	0.88	0.96	0.35	0.86	0.93	0.82	0.82	0.56	0.44	0.85	0.72	0.58	0.65
Non Current Assets Total	0.86	0.66	0.72	0.85	0.79	0.75	0.99	0.21	-0.42	0.47	0.56		0.99	0.41	0.59	0.94	0.73	0.48	0.87	0.66	0.57	0.63	0.84	0.93	0.98	0.44
Non Currrent Assets Other	0.79	0.56	0.62	0.8	0.71	0.68	0.99	0.28	-0.32	0.36	0.48	0.99		0.34	0.5	0.98	0.65	0.37	0.79	0.58	0.49	0.68	0.76	0.87	0.95	0.38
Other Assets	0.76	0.74	0.85	0.77	0.66	0.77	0.46	-0.71	-0.69	0.9	0.88	0.41	0.34		0.86	0.23	0.78	0.88	0.68	0.78	0.5	0.52	0.73	0.54	0.46	0.64
Cash And Short Term Investments	0.92	0.92	0.97	0.9	0.84	0.88	0.58	-0.46	-0.79	0.97	0.96	0.59	0.5	0.86		0.34	0.92	0.98	0.89	0.9	0.67	0.36	0.92	0.79	0.65	0.71
Net Receivables	0.67	0.38	0.48	0.7	0.56	0.53	0.94	0.39	-0.13	0.2	0.35	0.94	0.98	0.23	0.34		0.51	0.21	0.67	0.42	0.31	0.74	0.62	0.76	0.88	0.29
Common Stock Shares Outstanding	0.95	0.9	0.96	0.92	0.91	0.93	0.74	-0.37	-0.84	0.87	0.86	0.73	0.65	0.78	0.92	0.51		0.89	0.93	0.94	0.79	0.48	0.94	0.86	0.8	0.85
Short Term Investments	0.86	0.9	0.95	0.83	0.8	0.86	0.47	-0.56	-0.83	0.98	0.93	0.48	0.37	0.88	0.98	0.21	0.89		0.83	0.89	0.68	0.27	0.87	0.71	0.56	0.73
Non Current Liabilities Total	0.98	0.91	0.96	0.94	0.94	0.9	0.85	-0.13	-0.73	0.82	0.82	0.87	0.79	0.68	0.89	0.67	0.93	0.83		0.87	0.76	0.43	1.0	0.98	0.92	0.63
Capital Surpluse	0.9	0.96	0.93	0.88	0.95	0.99	0.68	-0.45	-0.93	0.86	0.82	0.66	0.58	0.78	0.9	0.42	0.94	0.89	0.87		0.89	0.36	0.9	0.8	0.74	0.73
Other Current Assets	0.72	0.89	0.76	0.65	0.92	0.86	0.58	-0.34	-0.94	0.67	0.56	0.57	0.49	0.5	0.67	0.31	0.79	0.68	0.76	0.89		0.04	0.77	0.72	0.68	0.55
Other Stockholder Equity	0.53	0.22	0.41	0.63	0.31	0.44	0.69	-0.03	-0.06	0.27	0.44	0.63	0.68	0.52	0.36	0.74	0.48	0.27	0.43	0.36	0.04		0.43	0.42	0.55	0.47
Total Liab	0.99	0.92	0.98	0.95	0.94	0.92	0.82	-0.2	-0.76	0.86	0.85	0.84	0.76	0.73	0.92	0.62	0.94	0.87	1.0	0.9	0.77	0.43		0.96	0.89	0.66
Long Term Investments	0.95	0.84	0.88	0.91	0.9	0.85	0.9	0.05	-0.63	0.7	0.72	0.93	0.87	0.54	0.79	0.76	0.86	0.71	0.98	0.8	0.72	0.42	0.96		0.96	0.55
Property Plant And Equipment Gross	0.89	0.73	0.78	0.86	0.85	0.8	0.98	0.13	-0.55	0.55	0.58	0.98	0.95	0.46	0.65	0.88	0.8	0.56	0.92	0.74	0.68	0.55	0.89	0.96		0.51
Preferred Stock Total Equity	0.68	0.6	0.71	0.69	0.61	0.71	0.48	-0.42	-0.66	0.64	0.65	0.44	0.38	0.64	0.71	0.29	0.85	0.73	0.63	0.73	0.55	0.47	0.66	0.55	0.51

Click cells to compare fundamentals

Arcus Biosciences Account Relationship Matchups

Arcus Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	203.1M	772.3M	1.6B	1.3B	1.1B	767.6M
Other Current Liab	1.5M	31.4M	52.0M	73M	65M	68.3M
Total Current Liabilities	22.7M	121.7M	166.1M	193M	184M	99.4M
Total Stockholder Equity	163.8M	502.3M	841.5M	657M	462M	428.3M
Other Liab	16.6M	133.1M	467.5M	378M	434.7M	456.4M
Net Tangible Assets	163.8M	502.3M	841.5M	657M	755.6M	793.3M
Property Plant And Equipment Net	9.3M	23.6M	137.4M	35M	51M	39.5M
Net Debt	(57.9M)	(158.2M)	(31.0M)	(86M)	(116M)	(121.8M)
Retained Earnings	(205.3M)	(328.2M)	(275.4M)	(542M)	(849M)	(806.6M)
Accounts Payable	4.7M	15.7M	10.3M	20M	17M	10.8M
Cash	57.9M	173.4M	147.9M	206M	127M	130.2M
Non Current Assets Total	10.4M	37.2M	910.6M	278M	264M	211.7M
Non Currrent Assets Other	872K	7.2M	591.2M	114M	106M	113.0M
Other Assets	1.1M	25.7M	10.7M	14M	16.1M	8.5M
Cash And Short Term Investments	188.3M	735.1M	681.3M	1.1B	759M	554.5M
Net Receivables	132K	1.7M	745M	43M	42M	39.9M
Common Stock Shares Outstanding	43.8M	54.8M	74.0M	72M	74M	57.8M
Short Term Investments	130.3M	555.2M	351.4M	803M	632M	380.7M
Liabilities And Stockholders Equity	203.1M	772.3M	1.6B	1.3B	1.1B	767.6M
Non Current Liabilities Total	16.6M	148.3M	584.4M	495M	449M	239.9M
Capital Surpluse	357.9M	369.1M	830.4M	1.1B	1.3B	1.4B
Other Current Assets	4.3M	1M	16M	15M	30M	31.5M
Other Stockholder Equity	369.1M	830.4M	1.1B	(7M)	(8.1M)	(7.6M)
Total Liab	39.3M	270.0M	750.4M	688M	633M	339.3M
Long Term Investments	0.0	6.4M	182.0M	129M	107M	59.2M
Property Plant And Equipment Gross	9.3M	10.8M	155.2M	58M	82M	47.6M
Total Current Assets	192.7M	735.1M	681.3M	1.1B	831M	555.9M
Accumulated Other Comprehensive Income	64K	44K	(1.3M)	(7M)	(6.3M)	(6.0M)
Non Current Liabilities Other	806K	148.3M	584.4M	140M	142M	140.0M
Property Plant Equipment	9.3M	10.8M	32.5M	135M	155.3M	163.0M
Current Deferred Revenue	7M	74.6M	102.0M	97M	91M	60.2M
Deferred Long Term Liab	15.8M	3.2M	4M	3M	2.7M	2.6M
Net Invested Capital	163.8M	502.3M	841.5M	657M	462M	473.8M
Net Working Capital	170.0M	614.1M	1.1B	874M	647M	598.2M
Short Term Debt	9.5M	27.9M	53.8M	3M	11M	18.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC